- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Gastrointestinal stromal tumour
- Meeting Date: March 2021
- Public Summary Document (PSD) March 2021 PBAC Meeting - (PDF 1391KB)
- Public Summary Document (PSD) March 2021 PBAC Meeting - (Word 1536KB)
Ripretinib – March 2021
Ripretinib: Tablet 50 mg; Qinlock®
Last updated
16 July 2021